MX2020000221A - Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. - Google Patents

Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.

Info

Publication number
MX2020000221A
MX2020000221A MX2020000221A MX2020000221A MX2020000221A MX 2020000221 A MX2020000221 A MX 2020000221A MX 2020000221 A MX2020000221 A MX 2020000221A MX 2020000221 A MX2020000221 A MX 2020000221A MX 2020000221 A MX2020000221 A MX 2020000221A
Authority
MX
Mexico
Prior art keywords
sequences
novel
amino acid
virus
strains
Prior art date
Application number
MX2020000221A
Other languages
English (en)
Inventor
Alfredo Nicosia
Stefano Colloca
Armin Lahm
Original Assignee
Nouscom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag filed Critical Nouscom Ag
Publication of MX2020000221A publication Critical patent/MX2020000221A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevas cepas de adenovirus con una alta inmunogenicidad y sin inmunidad preexistente en la población humana general. La falta de inmunidad preexistente se debe a nuevas regiones hipervariables en la proteína del hexón de la cápside adenoviral. Las nuevas cepas de adenovirus también tienen una capacidad mejorada para la reproducción. La presente invención proporciona secuencias de nucleótidos y aminoácidos de estas nuevas cepas de adenovirus, así como virus recombinantes, partículas tipo virus y vectores basados en estas cepas. Además, se proporcionan composiciones farmacéuticas y usos médicos en la terapia o profilaxis de una enfermedad, y métodos para producir un adenovirus o partículas tipo virus utilizando las nuevas secuencias, virus recombinantes, partículas tipo virus y vectores.
MX2020000221A 2017-07-05 2018-07-05 Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. MX2020000221A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17179825 2017-07-05
PCT/EP2018/068291 WO2019008111A1 (en) 2017-07-05 2018-07-05 AMINO ACID AND NUCLEIC ACID SEQUENCES OF ADENOVIRUS OF NON-HUMAN GREEN APES, VECTORS CONTAINING SAME, AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020000221A true MX2020000221A (es) 2020-08-13

Family

ID=59295008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000221A MX2020000221A (es) 2017-07-05 2018-07-05 Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.

Country Status (18)

Country Link
US (1) US11098324B2 (es)
EP (1) EP3649237B1 (es)
JP (1) JP7274222B2 (es)
KR (1) KR102582561B1 (es)
CN (1) CN111108192B (es)
AU (1) AU2018295421B2 (es)
BR (1) BR112020000145A2 (es)
CA (1) CA3066962A1 (es)
DK (1) DK3649237T3 (es)
ES (1) ES2906441T3 (es)
HU (1) HUE058778T2 (es)
IL (1) IL271835B2 (es)
MX (1) MX2020000221A (es)
PL (1) PL3649237T3 (es)
PT (1) PT3649237T (es)
RU (1) RU2762854C2 (es)
SG (1) SG11201913178WA (es)
WO (1) WO2019008111A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
EP4112036A4 (en) 2020-02-27 2024-04-17 Amorepacific Corporation COMPOSITION WITH IMPROVED USABILITY
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
US20230109362A1 (en) 2020-05-14 2023-04-06 Glaxosmithkline Biologicals Sa Viral biosensors
TW202208398A (zh) * 2020-07-01 2022-03-01 義大利商萊伊錫拉有限責任公司 大猩猩腺病毒核酸及胺基酸序列，包含彼之載體，及其用途
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022007774A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种新型黑猩猩腺病毒载体及其构建方法和应用
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0787200T3 (da) 1994-10-28 2005-08-15 Univ Pennsylvania Forbedret adenovirus og fremgangsmåder til anvendelse heraf
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US20030224372A1 (en) 2002-05-31 2003-12-04 Denise Syndercombe-Court Method for determining ethnic origin by means of STR profile
CA2553541C (en) 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
CA2583843C (en) * 2004-10-13 2010-09-21 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
DE602005025512D1 (de) * 2004-10-13 2011-02-03 Crucell Holland Bv Verbesserte adenovirusvektoren und deren verwendung
AU2006212885A1 (en) 2005-02-11 2006-08-17 Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
JP5809978B2 (ja) * 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−４３、−４５、−４６、−４７、−４８、−４９および−５０ならびにそれらの用途
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
KR101763093B1 (ko) * 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
WO2012023995A1 (en) * 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
WO2013036791A2 (en) * 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US9233153B2 (en) * 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
US20150157700A1 (en) * 2012-02-02 2015-06-11 GanVec, Inc. Adenoviral vector-based malaria vaccine
CN103966263A (zh) * 2013-02-04 2014-08-06 广州医学院第一附属医院 一种重组人3型腺病毒及其制备方法和应用
CN104419717B (zh) * 2013-08-23 2018-04-27 长春百克生物科技股份公司 逃避预存免疫的重组腺病毒及其构建方法和用途
WO2019118480A1 (en) * 2017-12-11 2019-06-20 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
TW202208398A (zh) * 2020-07-01 2022-03-01 義大利商萊伊錫拉有限責任公司 大猩猩腺病毒核酸及胺基酸序列，包含彼之載體，及其用途

Also Published As

Publication number Publication date
KR102582561B1 (ko) 2023-09-26
AU2018295421B2 (en) 2024-01-25
SG11201913178WA (en) 2020-01-30
RU2019144161A3 (es) 2021-08-05
WO2019008111A1 (en) 2019-01-10
IL271835B1 (en) 2023-04-01
PL3649237T3 (pl) 2022-03-28
EP3649237A1 (en) 2020-05-13
HUE058778T2 (hu) 2022-09-28
US11098324B2 (en) 2021-08-24
EP3649237B1 (en) 2022-01-19
AU2018295421A1 (en) 2020-01-02
CN111108192A (zh) 2020-05-05
CN111108192B (zh) 2023-12-15
RU2019144161A (ru) 2021-08-05
IL271835A (en) 2020-02-27
IL271835B2 (en) 2023-08-01
RU2762854C2 (ru) 2021-12-23
KR20200024296A (ko) 2020-03-06
US20210130848A1 (en) 2021-05-06
JP7274222B2 (ja) 2023-05-16
JP2020530761A (ja) 2020-10-29
DK3649237T3 (da) 2022-02-21
ES2906441T3 (es) 2022-04-18
BR112020000145A2 (pt) 2020-07-14
CA3066962A1 (en) 2019-01-10
NZ759892A (en) 2023-09-29
PT3649237T (pt) 2022-02-14

Similar Documents

Publication Publication Date Title
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
EP4218828A3 (en) Adeno-associated virus variant capsids and methods of use thereof
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
MX2019009720A (es) Metodos y composiciones para la transferencia de genes a traves de la vasculatura.
MX2023009627A (es) Capsides variantes de virus adenoasociados y metodos de uso de las mismas.
EP4272728A3 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
RU2015135890A (ru) Композиция вакцины
MX2015005505A (es) Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano.
AU2014203512B2 (en) Recombinant virus-like particles encoded by multi-gene vector
WO2014078688A3 (en) Recombinant adenoviruses and use thereof
IN2015DN02546A (es)
JP2016513115A5 (es)
JP2016146837A5 (es)
MX2020010466A (es) Vectores de virus que evitan anticuerpos.
MX354750B (es) PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
TR201908199T4 (tr) HPV'ye karşı aşılar.
EA200702190A1 (ru) Вакцинная композиция
WO2011130749A3 (en) Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
MX2020010464A (es) Vectores de virus que evitan anticuerpos.
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
WO2010079991A3 (ko) 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균
MX2022016287A (es) Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas.
AR101468A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9